Randomized Phase II Trial of Docetaxel plus Nivolumab or Docetaxel alone
in patients with advanced squamous or non-squamous NSCLC and previous clinical benefit on treatment with a PD-1 or PD-L1 inhibitor

IRB/UVA Tracking #
20704
Contact First Name

Gracie Tubbs Hockenberry

Contact Email
Contact Phone
Phase
II
Primary purpose
Treatment
Cancer PI
Richard Hall
Status
OPEN TO ACCRUAL